124 related articles for article (PubMed ID: 11365860)
21. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.
Seminari E; Maggiolo F; Villani P; Suter F; Pan A; Regazzi MB; Paolucci S; Baldanti F; Tinelli C; Maserati R
J Acquir Immune Defic Syndr; 1999 Dec; 22(5):453-60. PubMed ID: 10961606
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
Moolasart P; Likanonsakul S
Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
[TBL] [Abstract][Full Text] [Related]
23. ACTG 343: three drugs better than two for maintaining HIV suppression.
Bowersox J
NIAID AIDS Agenda; 1998 Mar; ():1-2, 10-1. PubMed ID: 11365088
[TBL] [Abstract][Full Text] [Related]
24. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy.
Roca B; Gómez CJ; Arnedo A
J Infect; 1999 Sep; 39(2):141-5. PubMed ID: 10609532
[TBL] [Abstract][Full Text] [Related]
25. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
26. dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
Skowron G
Antivir Ther; 1998; 3 Suppl 4():61-2. PubMed ID: 10723513
[TBL] [Abstract][Full Text] [Related]
27. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
[No Abstract] [Full Text] [Related]
28. Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir.
Anderson RD
Antivir Ther; 1998; 3 Suppl 4():63-4. PubMed ID: 10723514
[TBL] [Abstract][Full Text] [Related]
29. Salvage therapy studies.
Proj Inf Perspect; 1998 Sep; (25):7. PubMed ID: 11365850
[TBL] [Abstract][Full Text] [Related]
30. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
31. The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
Reijers MH; Weverling GJ; Jurriaans S; Roos MT; Wit FW; Weigel HM; Ten Kate RW; Mulder JW; Richter C; Ter Hofstede HJ; Sprenger H; Hoetelmans RM; Schuitemaker H; Lange JM
AIDS; 2001 Jan; 15(1):129-31. PubMed ID: 11192858
[No Abstract] [Full Text] [Related]
32. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
[TBL] [Abstract][Full Text] [Related]
33. Another take on when to start and how to succeed.
Friedland GH
AIDS Clin Care; 2001 Sep; 13(9):82. PubMed ID: 11547600
[No Abstract] [Full Text] [Related]
34. New triple combo trial opens.
Vazquez E; Whitfield L
Posit Aware; 1997; 8(6):12. PubMed ID: 11364852
[TBL] [Abstract][Full Text] [Related]
35. Hydroxyurea for HIV infection.
Zachary KC; Davis B
AIDS Clin Care; 1998 Apr; 10(4):25-6, 32. PubMed ID: 11365149
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
37. Nonnucleoside reverse transcriptase inhibitors.
Murphy RL
AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
[TBL] [Abstract][Full Text] [Related]
38. Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
Spear GT; Olinger G; Sullivan BL; Landay AL; Kessler H; Connick E; Kuritzkes D; St Clair M; Spritzler J; Wu H; Lederman MM
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1713-5. PubMed ID: 10606095
[No Abstract] [Full Text] [Related]
39. An open-label trial of stavudine, lamivudine and efavirenz in the treatment of HIV-positive, treatment-naive patients, and implications for clinical practice.
Elion R; Green L; Cohen C; Green S; Baird I; Schrader S; Ward D
Antivir Ther; 1999; 4 Suppl 3():89-91. PubMed ID: 16021878
[TBL] [Abstract][Full Text] [Related]
40. Antiviral update.
PI Perspect; 1996 Nov; (No 20):8-9. PubMed ID: 11363972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
